Introduction
A report of the UK Royal College of Physicians entitled 'Nutrition and Patients: A Doctor's Responsibility', published in July 2002 [1] , highlighted again the importance of nutritional care for vulnerable groups such as undernourished elderly people, particularly those who are hospitalized or institutionalized. Older people have longer periods of illness and longer hospital stays [2] , and data show that up to 55% of elderly hospitalized patients are undernourished on admission [3, 4] .
Malnutrition is associated with poorer recovery in a broad range of patients and conditions [5, 6] , and furthermore, nutritional status has been shown to decline during hospitalization [3, 7] . This has led to the hypothesis that providing nutritional support to those at risk of malnutrition will have beneficial effects on outcome. The best way to establish this is to demonstrate it in a randomized controlled trial (RCT).
A systematic review of RCTs by Potter et al. [8] in 1998 examined the effects of oral and enteral protein and energy supplementation in trials involving adults of all ages with any medical or surgical condition. Supplementation seemed to improve the nutritional indices of adult patients, but there were insufficient data in trials which met strict methodological criteria to be certain if mortality was reduced.
A Cochrane Review of dietary advice for illness-related malnutrition in adults of all ages was also carried out by Baldwin et al. [9] . There was insufficient evidence to establish whether dietary advice alone improves the outcomes, however the limited information available suggested that weight gain was greater in people who also received supplements, with or without advice. Oral nutritional supplements are widely prescribed for older people both in hospital and in the community and it is important to establish whether they are clinically effective, by reviewing trials of oral protein and energy supplementation and including more recent better quality trials.
Methods
Studies were identified, and the analyses were carried out according Cochrane methodology [10] . The search (until the end of 2002), included the following databases: the Cochrane Controlled Trials Register, Medline, Embase, Biosis and CAB abstracts.
Selection of Studies
We included randomized or quasi-randomized trials with a minimum intervention of 1 week. Groups of study participants had to have a minimum average age of 65 years. All patient groups were included, with the exception of people in critical care or recovering from cancer treatment.
We included commercial sip feeds, other milk-based supplements and fortification of normal food sources. We excluded studies of specially designed immunomodulatory supplements or supplements of specific amino acids. The full description of the search strategy is available elsewhere [11] . If necessary, trialists were contacted for further information on methodology and data.
The following outcomes were examined as pre-specified in our protocol: all-cause mortality; number of people with morbidity or complications; length of hospital stay; functional status; participants' perceived quality of life; percentage weight change; percentage change in mid-arm muscle circumference (MAMC); acceptance of the supplement, and side effects.
Extraction of outcome data from the included trials and quality assessment of trials was carried out independently by 2 reviewers. All differences were resolved by discussion.
Data were combined for meta-analysis for the dichotomous variables mortality and number of people with complications. For each study relative risks (RRs) were calculated, the results were combined using fixed effects models with 95% confidence limits.
Because length of hospital stay data were likely to be positively skewed and therefore not suitable for meta-analysis, the effect of supplementation on length of stay was tested using the Wilcoxon signed ranks test.
Weighted mean difference and 95% confidence intervals were calculated for percentage weight change and percentage MAMC change using a fixed effects model. For meta-analyses the same methods were used to standardize for missing data as previously used by Potter et al. [8] .
Where there was evidence of heterogeneity in the meta-analyses a random effects model was applied. Heterogeneity between comparable trials was explored using a standard 2 test, the level of statistical significance used was p Ͻ 0.1 (two-sided).
Pre-specified subgroup analyses of the mortality data were carried out: (a) baseline nutritional status as reported by the investigators (nourished, undernourished); (b) mean age (Ͻ75 years, Ն75 years); (c) amount of kilojoules provided in supplement (Ͻ1,674 kJ (400 kcal), Ն1,674 kJ); (d) duration of intervention (Ͻ35 days, Ն35 days), and (e) environment (hospitalized, not hospitalized).
An exploratory subgroup analysis was also carried out on the basis of diagnostic group, providing 3 or more trials were available. The diagnostic groups were patients with hip fracture, chest conditions, stroke, congestive heart failure, geriatric conditions (trials which included frail patients with a variety of pathologies), and older surgical patients.
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A sensitivity analysis was carried out including only trials which reported clearly concealed randomization.
Description of Studies
More than 200 potentially relevant trials were identified from the searches. Two reviewers independently assessed these trials. As a result of mutual agreement, 35 have been included in the review with a total of 3,242 individually randomized participants (table 1) . Most were patients with various pathologies in long-stay/care of the elderly/hospital wards or nursing homes (15 trials), or older people at home (4 trials) or in a metabolic unit (1 trial). The remaining trials included particular groups with hip fracture (6 trials), stroke (1 trial), congestive heart failure (1 trial), chest conditions (5 trials), or older surgical patients (2 trials).
Most trials used commercial supplements. About 50% of trials offered Ն1,674 kJ/day (400 kcal). The period of the intervention ranged from 7 days to 18 months. The intervention time was Ն35 days for about 50% of trials.
Results

Methodological Quality of Included Studies
Concealment of allocation was reported in 9 studies. An intention-to-treat analysis was reported in 17 studies. Only 7 studies clearly reported taking action to blind outcome assessors such that bias was unlikely (table 1) . Full details of the quality assessment are available elsewhere [11] .
Outcomes
Mortality:
Results for the meta-analysis were obtained from 24 trials (2,387 participants). Nutritional supplementation by the end of follow-up was associated with reduced mortality (RR 0.69, 95% CI 0.54-0.88; fig. 1 ).
Subgroup Analyses (table 2) The results were consistently statistically significant when limited to trials where participants were undernourished, Ͼ75 years, were offered Ն400 kcal (1,674 kJ)/day in the supplement, when supplementation was continued for Ն35 days, and when participants were hospitalized. The results were also statistically significant when limited to trials including frail patients with a variety of geriatric conditions. Sensitivity Analyses: The results for mortality for all trials were consistent when analysis was restricted to trials with clearly concealed randomization (n ϭ 1,536; RR 0.63, 95% CI 0.48-0.83).
Number of Complications: Data were combined for meta-analysis for the total number of complications from 10 studies (n ϭ 876). The risk of complications in supplemented groups was not significantly different from the control groups (RR 0.92, 95% CI 0.78-1.09; fig. 2 ).
Length of Stay: Data on length of hospital stay were combined from 8 studies (1,135 patients; table 3), including 1 study with 3 subgroups [12] . The mean length of stay was shorter for the supplemented groups (18.9 versus 25.4 days) but this was not statistically significant, (Wilcoxon signed ranks test p ϭ 0.113). Functional Status: Functional status or quality of life measures were reported in 21 studies, the outcomes measured were diverse, and few suggested any functional benefit. Fewer bed disability days were reported in the study by Payette et al. [13] . Gray et al. [14] reported that the number of falls was lower among those receiving supplements. Larsson et al. [7] reported a significant improvement in the activity rating in the supplemented group at 8 weeks compared to the control group.
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The Barthel activities of daily living (ADL) index [15] was measured in 6 studies. Only 1 study [16] reported a lower level of functional ability in the control group. Potter et al. [12] reported a significant improvement with supplements only in a subgroup of very malnourished patients. Volkert et al. [17] found an improvement in the ADL index only a subgroup with good acceptance of the supplement.
Four studies in patients with chronic obstructive pulmonary disease measured lung function. Only 1 study [18] found a sustained statistically significant improvement in forced vital capacity with supplements.
No statistically significant effects between groups were reported from quality of life questionnaires.
Weight Change: In data from 24 trials (1,867 participants) the pooled weighted mean difference for percentage weight change showed a benefit from supplementation of 2.4% (95% CI 1.9-3.0; fig. 3 ).
MAMC: In data from 13 trials (1,187 participants) the pooled weighted mean difference for percentage MAMC change showed a benefit from supplementation of 1.4% (95% CI 0.19-2.6; fig. 4 ). 
Acceptance of the Supplement and Side Effects
Supplemented intake was significantly greater than non-supplemented intake in most studies. Fiatarone et al. [20] , however, found that the increase in intake from the supplements had been offset by a reduction in normal food intake. Thirteen studies reported that the supplements were well accepted by most patients. Problems with acceptance were reported by Gray et al. [14] where 36% of potentially eligible participants refused to participate mainly because they did not wish to take a supplement. Volkert et al. [17] found that 45% of participants had poor acceptance. Problems with nausea, gastrointestinal discomfort and diarrhea attributed to the supplements were also reported in a 4 studies.
Discussion
This review suggests that there may be a beneficial effect of supplementation on mortality. However doubts remain because of the poor quality of most included trials.
Oral The data were unable to suggest reduced hospital stay or complications, which might be expected to accompany reduced mortality. The duration of the intervention was probably too short in most trials to realistically improve these outcomes. However, results of the subgroup analysis of mortality data do follow a pattern of benefit which may be expected clinically.
Supplementation produced a small but consistent weight gain, which could be fat, muscle or water. A gain of fat mass or water will not improve muscle strength. The data from MAMC also suggests a small gain, possibly in muscle mass. However, Fiatarone et al. [20] proposed that exercise is also required to produce a significant improvement in muscle strength and function.
Since few studies used placebo supplements, bias may result from supplemented patients receiving a higher standard of care, or from outcome assessors being aware of treatment status. Only 7 trials reported that outcome assessors were blinded.
Nearly 50% of trials did not report an intention-to-treat analysis and participants in some studies were excluded from the analysis because they were unable to take the supplements.
It is well known that frail elderly patients have low intakes and can find it difficult to consume oral supplements. Indeed, it has been suggested that even with extra feeding support from specially trained staff, improvement in the nutritional status of older patients may not be achieved [21] . Problems with acceptance of the supplement were reported in some trials, but the methods of delivery of the supplement were poorly described. The mode and timing of distribution, and the volumes offered may be key factors in maximizing acceptance. A unique pragmatic approach used by Potter et al. [12] was to administer a small volume (120 ml) during the drug round as a part of routine medical care. This was well accepted and resulted in a significantly higher energy intake and weight gain compared to the control group. However, there are major organizational and practical challenges to achieving improvements in nutritional intake, and the best methods have still to be established. The main concern of most trials was the effect of supplementation on nutritional status. These results suggest that supplements can have a useful role to play in improving the nutritional status of elderly people. However, older people are very heterogeneous, as reflected in the trials, and some patients groups may benefit more than others. There were insufficient trials of most diagnostic subgroups (such as patients with stroke) to undertake separate meta-analyses.
Although the evidence was limited, the meta-analysis suggested that hospitalized patients were more likely to benefit from supplementation than older people in the community, even though most oral supplements are prescribed in primary care. It is essential that we aim to find evidence-based methods to improve the nutritional status of those 'at risk' in the community, before they become malnourished or are admitted to hospital.
In conclusion, adequately powered, well-designed trials with clearly defined patient groups, both in hospital and in the community, are still required to determine whether supplements can be beneficial in terms of mortality, complications, length of hospital stay, functional status, quality of life and cost-effectiveness. oncology conference, they would say look at the wonderful results we have, we have a 2-week later disease progression. There was of course no effect on mortality and there was a longer stay in the hospital due to chemotherapy, but this is wonderful and the whole world will start to use this treatment. Now we look at the hardest end point, we say well mortality, even if there is a small extension of life it is not that important and there are complications. How was functionality in old patients, this is very important; how was the quality of life, and what end point should we rather look at with nutrition?
Dr. Milne: I absolutely agree with what you say. The problem with doing systematic reviews is that you can only use what the trials have provided in terms of outcomes. A lot of these trials have been designed to look at nutritional outcomes and have reported mortality. Some of the more recent ones are focusing more on outcomes that are important to patients and treatment providers. There are more recent trials that have looked at functional outcomes such as handgrip and quality of life outcomes [1, 2] . Just recently I have been able to look at a meta-analysis of handgrip strength studying the changes in handgrip, but there was no significant effect on handgrip. I will also present the findings in terms of quality of life and functional outcomes in a descriptive section of the updated Cochrane Review rather than using a meta-analysis method.
Dr. Lochs: Couldn't that be one thing this conference could do to make recommendations? What should we study in the future? Dr. Hébuterne said nutritional status is more or less what we are looking for. You are also looking in the same direction and then we end up with a very thin database. Perhaps we should then say our recommendations for future studies would be to look at this and this and this parameter. I don't know but perhaps it is that something we could end up with this conference.
Dr. Milne: That would be very useful. I think we also have to take into account the different diagnostic groups and the different outcomes which are relevant to those, for example, for patients with chronic obstructive pulmonary disease (COPD) you may be interested in lung function, and in patients with hip fracture you may be interested in how soon they are up and walking and their ability to walk and that sort of thing. So it will be difficult to find something that suits all these different trials, but I think it will be useful to get some kind of consistency so we can actually look more carefully at these outcomes.
Dr. Roessle: It is already difficult to design double-blind randomized clinical trials for parenteral and enteral nutrition. If you are designing trials for oral nutrition the task is even more complicated because by definition you have no placebo treatment and you cannot run a true double-blind randomized clinical trial. I wonder whether in your meta-analysis you have been really fair in picking up the trials because the only way to do this is to compare with no treatment and this is not a blinded way to analyze. If you look at all the other trials which are not randomized or not comparative, they might also give valuable results because the ideal trial is not possible. I would like to have your advice on how to design future trials with oral supplements to be as fair as possible.
Dr. Milne: I think in some way it is easier to design trials of oral supplements than it is to design trials of enteral or parenteral feeding. What you need to do is compare your provision of supplements with usual care. I think the problem is that there are deficiencies in the way we use supplements at the moment and there are ways in which we can provide better care in terms of oral supplementation. So if we design an intervention which we think is practical and usable on a ward situation, hopefully that will go beyond what is usual practice at the moment, and I don't think there is any ethical problem then with developing a trial. I can give you the example of one of my coworkers. Potter et al. [3] recently ran a trial of oral supplements which was designed to compare usual practice, which may include interventions by the dietician and anything that would normally happen on the ward, with providing small quantities of more energy-dense oral supplements which were prescribed on the drug cardex and then administered to the patients. This was a very pragmatic approach, but a lot of the problems with supplements have to do with wastage, meaning that these supplements may sit on the bedside lockers and don't get consumed, so there is wastage. So it helps overcome such problems. I agree that we also need to take other kinds of nonrandomized trials into account and not just focus completely on randomized trials.
Dr. Elia: One of the advantages of undertaking meta-analyses such as these is that you may be able to identify groups of patients who may benefit from particular interventions and those who don't. In relation to functional outcomes it seems reasonable to assume that those people who aren't malnourished may not respond to the supplement in the same way as those who are malnourished and therefore have already lost some function. Some studies and meta-analyses have split the groups of patients according to some form of index of nutritional status, one of the simplest of which being body mass index. Have you considered this issue in your meta-analysis?
Dr. Milne: I haven't looked at functional outcomes in terms of nutritional status, but I think it would be useful to do that.
Dr. Elia: All outcomes including mortality would be interesting to look at. Dr. Milne: I have looked at mortality and divided the results looking at the subgroup analyses of nutritional status, those who were defined as at nutritional risk compared with others who were not but who hadn't been reported as being at nutritional risk. Certainly the evidence for mortality suggested that those who had been defined as being at nutritional risk were benefiting more.
Dr. Powell-Tuck: Many congratulations on this meticulous work, it is very helpful indeed. Firstly a follow-up on what Dr. Elia was saying. I think there are some patients in whom we are trying to maintain weight, maintain quality of life, and in these of course you are not going to expect to see a change. The positive outcome is no change, in other words it is not worsening. That is the observation. The question is, you had 8 trials for respiratory diseases and I wondered why you haven't gone ahead and analyzed those, and whether you could make any comments about that particular group of illnesses? Dr. Milne: There were 8 trials of COPD patients. I think all these diagnostic groups may have different responses to supplementation and that is certainly true in patients with COPD. I didn't look at mortality as a subgroup because there was not sufficient information available for the outcomes of interest, in that mortality data were not there. In the review I reported the functional outcomes which were things like change and lung performance, but again from the way that the results were provided in the articles, I was not able to combine them. So it will be descriptive rather than using a meta-analysis.
Dr. DeLegge: Just two questions for you. One is, would these people in the control groups have free access to food, meaning if they wanted an extra candy bar or Snickers or Coca Cola they could have it if they wanted it? The second question is, one of the more difficult problems we have with oral supplements is compliance and in fact our recent hospital-based survey showed that compliance with oral supplements was about 18% of the patients. So I don't think you presented the intention-to-treat data, but if you look at intention-to-treat sub-analyses, did you have similar results?
Dr. Milne: The results were presented as they were described in the trials, so some used an intention-to-treat analysis and some did not. So I didn't split them by an intention-to-treat analysis. But I agree that a lot of the problems with our oral supplements is the fact that patients aren't very compliant so in some ways we need to find better ways of providing oral nutrition support. There is a lack of trials which look at other methods, for example fortifying normal food sources, or even trials which provide extra support or extra help for patients in terms of helping them eat their meals Oral Protein and Energy Supplementation in Older People or take their supplements. So there are different ways that we should be looking at in terms of helping patients in hospital and, also more importantly, the evidence is much poorer in terms of community-living older people, and trying to tackle nutritional risk before patients are admitted to the hospital in the first place.
Dr. DeLegge: Just make sure you keep a positive spin. Dr. Thomas: A really nice job and I know you are limited into a large extent by the trials you have to work with. One of things that seems clear from looking at the data is that there are populations of people who do not respond at all to nutritional supplements and there are populations that appear to respond. Since you did have a positive effect, all be it a small effect, it would be nice to see if the trials would allow you to eliminate certain cachexia states that have not been shown to respond at all, and then see if you have enough strength left in the trials of people who are likely to respond to increase the magnitude of the effect. That may or may not be possible but I would love to see you try to do that.
Dr. Milne: I think the inflammatory response was discussed yesterday; people with different diseases will have different responses. From what I understood, practically every disease has some degree of inflammatory response but perhaps some diseases like COPD will be more affected. At the moment I don't feel I have enough knowledge to try and start splitting them by those that may have that response. It is something that will perhaps be done in the future.
Dr. Labadarios: I would like to support Dr. Loch's proposal regarding the criteria for such studies. It is rather important that we collectively do something about it otherwise in 10 years time we will probably be sitting in a different place but we will have the same results. The quality of the trials is too poor to make a difference or to draw a conclusion, and I think that it reflects badly on the leadership of nutrition quite honestly. Somehow everybody around this table had input in getting these protocols approved. So I think it is a constructive and worthwhile undertaking which should be supported. The question is, and I hope I understood your slide correctly, the in-hospital population appeared to do significantly better than the community-based population. Could you expand a little bit on this, were you able to decide why that was the case?
Dr. Milne: There were 10 trials in the hospital and only 5 in the community, so actually there is less evidence from the community as opposed to evidence of no effect. In terms of compliance it seems to be more of a problem with patients in the community taking their supplements than those being supervised in hospital. Some of the recent trials with community patients would suggest that compliance is a problem.
Dr. Bozzetti: I have a couple of questions. First, what is the reason for dividing patients into groups receiving more or less than 400 kcal? Would it not be more informative or useful to express the kilocalories per kilogram of body weight? Secondly, is there a minimum time necessary to observe a benefit with supplements?
Dr. Milne: These were rather arbitrary cutoffs established before we actually looked at the trials. We didn't know how many calories were going to be provided. But just looking at those who were given fewer calories compared to more calories, I think there is a limit to how much you can read from the results because a lot of it depends on compliance, and even if you have fewer calories but actually consume them all, it is likely to be more important than being offered 1,000 kcal/day and only taking 500. I think it is probably more important to look at the length of time patients were supplemented and also the length of time patients were followed up, which is another deficiency in the trials included because really we are interested in outcome at 6 months, a year down the line rather than within a month of supplementation. So it was an attempt to try and look quantitatively at those who were given either more or less supplements for longer or shorter periods, but there is a limit to how much you can read into the results, I agree.
Oral Protein and Energy Supplementation in Older People
Dr. Correia: I am going to go further into the Dr. Labadario's and Dr. Loch's comments. As those who are leaders in thinking in the area of nutrition, we should try to establish some basic concepts. I go further by saying that we are nowadays discussing molecular nutrition, and we forget basic things such as should we calculate our energy requirements based on actual or ideal body weight. We even forget or we even don't know exactly the definition of what malnutrition is and how to assess malnutrition. So I think for the future, in order to have better studies, we definitely should define these basic issues so that when we analyze independently, whether it is a meta-analysis or not, we can come to the same conclusion based on what we are referring to as malnutrition. We have recently reviewed data on oral supplements because my group is completing a paper on the use of oral supplements. One of the difficulties we found is that the articles do say that they gave an average of 100 kcal as a supplement, but most of them forgot to tell us that if by feeding these patients with oral supplements what the amount of the oral food was. So my question is, when we give supplements aren't we changing food for another artificial nutrition? Aren't these patients decreasing what they are eating? From the articles I have read, I can tell you that 90% of them did not have a simple sentence about the amounts of calories that these patients took while eating regular food. So I think it is very difficult to analyze all of these data based on results if we don't measure what the patients really eat.
Dr. Milne: A lot of the trials that I included made some attempt to measure the intake of the patients. I admit that the methods they used were not ideal and there is probably a potential for quite a lot of error, but the results would suggest that patients do increase their intake with oral supplements although, as you can see from the effect on weight change, it is only 2.5%, which for a 50-kg person may mean that they only gain less than 1.5 kg. If they were consuming all the supplements in addition to a normal diet you would expect the weight change between the two groups to be more. So there is probably some compensation going on in terms of normal diet but I think we can see that they actually do increase their intake, but probably not as much as we would like, and most studies reported good compliance with supplements. I think a difference may be between what happens in the trials and what happens in a normal ward situation.
Dr. Elia: We have looked at the effect of supplements in suppressing food intake. The results from the literature are varied, but in general it seems that most of the supplements in the studies that we were able to analyze added to food intake. This is interesting in itself, but the extent to which it was additive varied according to nutritional status. Those who were undernourished, defined as a body mass index of less than 20, were more likely to have a higher additive intake than those who were wellnourished. The effect tended to decrease with time.
Dr. Milne: I accept your point. Dr. Biesalski: There might be one other problem with those studies. If you include fortified food, etc., and keep in mind that the balanced or misbalanced micronutrient status might have a big impact on quality of life, B vitamins and depression or lowdose multivitamins for example might have an influence on the immune system. So the studies have to be separated between those who add some B vitamins and those who allow that they might be added. This is another point that might have a big impact on the outcome of these studies.
Dr. Powell-Tuck: I want to follow on Dr. Elia's comment, and I actually disagree with Dr. Correia because I think the way you design a trial depends on the question you are asking. If firstly, as Dr. Elia said, we have excellent evidence not only from his group's work but also from your own group's work, I think that supplementation is effective in increasing intake. So that may not be the question that you are seeking to answer again because it has been answered very fully already. Also if one was on full dietary assessment of every patient, one is liable to confine one's trials to rather small Oral Protein and Energy Supplementation in Older People numbers because it becomes impractical to do this on a large scale. So if you are actually asking the question whether a particular intervention with a particular supplement is beneficial on length of stay, it may be quite unnecessary to make the measurements of additional food intake. You are interested in the outcome of that intervention and that way you may have the chance to do the big scale studies, which I believe we need in this field on a practical and financially basis.
Dr. Milne: I absolutely agree, and this is the type of trial that Potter et al. [3] did with acute elderly patients. It was a pragmatic practical trial and they measured the clinical outcomes. So basically we get the answer that we need rather than looking at whether the patients have increased their intake or whether their nutritional status has changed.
Dr. Lochs: I agree with you, but doesn't it help to interpret the results if you know the supplements reduced the oral intake, and then you have an easier time to interpret if you find something or not?
Dr. Milne: One time when it will be really useful to do, is if you run a trial and find no clinical effects at all. At least if you have actually looked at changes in intake then you can perhaps say the reason why we didn't find an effect was that patients didn't actually increase their intake, and I think that is an important point.
Dr. Powell-Tuck: May I just come back. In the ideal world of course one would love to have all the data, but what I worry about is the practicalities here. You have to decide what you are going to do; you decide your budget; what you can achieve, and I think it is very important sometimes to simplify things down so that you could do large numbers to really answer the question does an intervention have an effect. I think we sometimes focus too much on nutritional outcome and not enough on economically important outcome. That is the point I am trying to make.
Dr. DeLegge: That is why I think in these particular trials the intention-to-treat seat is important because you flash out all those ideas; meaning if you have a new drug but the compliance at home is poor when the drug has to be taken 6 times a day, the drug, although it may be great, may not be very effective practically. So is there any possibility of reanalyzing the intention-to-treat studies that you have?
Dr. Milne: I think it is something that would be a possibility. The data are limited so you are starting to getting down to only a few studies. But I absolutely agree, I think a lot of the older studies were done on efficacy rather than effectiveness, and there are not many trials which you could say were pragmatic trials where they haven't actually brought in people to support the trial and make sure the patients take their supplements. But that still leaves us with the problem of not really knowing what happens in practice and not having interventions which we know if they are put in place on a ward will have a beneficial effect because they take into the account the problems that happen on the wards. Furthermore, you can't look at which interventions are likely to be more cost-effective unless you look at pragmatic trials.
